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OBJECTIVE—Nicotinamide adenine dinucleotides (NAD
 and
NADH) play a crucial role in cellular energy metabolism, and a
dysregulated NAD
-to-NADH ratio is implicated in metabolic
syndrome. However, it is still unknown whether a modulating
intracellular NAD
-to-NADH ratio is beneﬁcial in treating meta-
bolic syndrome. We tried to determine whether pharmacological
stimulation of NADH oxidation provides therapeutic effects in
rodent models of metabolic syndrome.
RESEARCH DESIGN AND METHODS—We used -lapachone
(L), a natural substrate of NADH:quinone oxidoreductase 1
(NQO1), to stimulate NADH oxidation. The L-induced pharma-
cological effect on cellular energy metabolism was evaluated in
cells derived from NQO1-deﬁcient mice. In vivo therapeutic
effects of L on metabolic syndrome were examined in diet-
induced obesity (DIO) and ob/ob mice.
RESULTS—NQO1-dependent NADH oxidation by L strongly
provoked mitochondrial fatty acid oxidation in vitro and in vivo.
These effects were accompanied by activation of AMP-activated
protein kinase and carnitine palmitoyltransferase and suppres-
sion of acetyl-coenzyme A (CoA) carboxylase activity. Consis-
tently, systemic L administration in rodent models of metabolic
syndrome dramatically ameliorated their key symptoms such as
increased adiposity, glucose intolerance, dyslipidemia, and fatty
liver. The treated mice also showed higher expressions of the
genes related to mitochondrial energy metabolism (PPAR co-
activator-1, nuclear respiratory factor-1) and caloric restriction
(Sirt1) consistent with the increased mitochondrial biogenesis
and energy expenditure.
CONCLUSIONS—Pharmacological activation of NADH oxida-
tion by NQO1 resolves obesity and related phenotypes in mice,
opening the possibility that it may provide the basis for a new
therapy for the treatment of metabolic syndrome. Diabetes 58:
965–974, 2009
M
etabolic syndrome comprises a constellation
of speciﬁc cardiovascular disease risk factors
whose underlying pathophysiology is related
to insulin resistance (1). All the components
of metabolic syndrome such as dyslipidemia, high blood
pressure, glucose intolerance, and liver and muscle fat
inﬁltration are related to central obesity. It has been
reported that the imbalance between energy intake and
expenditure is clearly related to obesity and metabolic
disorders (2). Less calorie intake and more energy expen-
diture through exercise are the most effective modalities
for the prevention of metabolic syndrome (3). Calorie
restriction (4) and increased physical activity, in fact, have
been known to prevent and reverse the phenotypes of
metabolic syndrome by activating metabolic regulator
proteins such as Sirt1, AMP-activated protein kinase
(AMPK), and PPAR coactivator-1 (PGC-1) (5–8). The
protective effects of these proteins against metabolic
syndrome are closely linked to increased mitochondrial
functions (9,10).
Previous studies have indicated that nicotinamide ade-
nine dinucleotides (NAD
 and NADH) are fundamental
mediators of energy metabolism (11,12). An increased
intracellular level of NAD
 activates Sirt1-dependent met-
abolic control, mediating the effects of calorie restriction
in mammals (5). Moreover, pharmacological activation
of Sirt1 prevents development of metabolic syndrome
through the synergistic activation of AMPK and PGC-1,
which results in elevated mitochondrial respiration (10).
Mitochondrial NADH is a critical electron donor in mito-
chondrial electron transport chain, and cytosolic NADH
can be shuttled into mitochondria, thereby affecting mito-
chondrial oxidative phosphorylation. Based on these
ideas, we hypothesized that transiently increased NAD

levels coupled with decreased NADH levels in cytosol
provoke mitochondrial oxidative phosphorylation and that
long-term induction of a higher NAD
-to-NADH ratio
mimics the effects of calorie restriction.
NADH:quinone oxidoreductase 1 (NQO1) is a cytosolic
antioxidant ﬂavoprotein that catalyzes the reduction of
highly reactive quinone metabolites by using NADH as an
electron donor (Fig. 1A) (13). A naturally occurring com-
pound, -lapachone (L) is a substrate of NQO1 and its
treatment to cancer cells results in depletion of NADH and
consequent apoptosis (14). ArQule (ARQ) 501, a synthetic
version of L, is a promising anticancer drug currently in
multiple phase II clinical trials. Its anticancer action is
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DIABETES, VOL. 58, APRIL 2009 965based on the ﬁndings that cancer cells usually exhibit a
high level of NQO1 expression. In this study, we investi-
gate the effect of L on the metabolic syndrome of rodent
models to examine whether pharmacological induction of
a high NAD
-to-NADH ratio is beneﬁcial in treating the
key components of metabolic syndrome.
RESEARCH DESIGN AND METHODS
Animal models. All animal procedures were in accordance with the guide-
lines issued by the Institutional Animal Care and Use Committee of the
Chungnam National University School of Medicine. Otsuka Long Evans
Tokushima fatty rats were from the Otsuka Research Institute. Male ob/ob and
C57BL/6 mice were from The Jackson Laboratory and housed four per cage in
a room maintained at a constant temperature (25°C) in a light:dark 12:12-h
schedule. Four-week-old male C57BL/6 mice were fed a high-fat diet (Re-
search Diets, 24% [w/w], 45% calories as fat) ad libitum for 7 weeks. Groups of
mice were untreated, vehicle treated (calcium silicate), pair fed, or L treated
(p.o., micronized particles of L coated with calcium silicate). Body weight
and food intake were measured daily. At the end of experiments, one mouse
from each group was anesthetized and examined by MRI. Other mice were
dissected, and tissue weight was measured.
Antibodies, plasmids, and reagents. Anti-AMPK antibody was purchased
from Cell Signaling Technology (for immunoblotting) and Upstate (for immu-
noprecipitation). Anti–phospho-T172 AMPK, anti–acetyl-CoA carboxylase
(ACC), and anti–phospho-S79 ACC antibodies were from Cell Signaling
Technology. Anti-NQO1 antibody was from Santa Cruz Biotechnology. Anti-
OxPhos Complex II subunit antibody was from Molecular Probes. Anti–-
tubulin antibody was from Sigma. pEFIRES HA-NQO1, and pEFIRES HA-
NQO1C609T plasmids were gifts from Dr. Gad Asher (Weizmann Institute of
Science, Rehovot, Israel). Other reagents were purchased from Sigma, Cal-
biocam, or Amresco.
Liquid chromatography–mass spectroscopy/mass spectroscopy analysis.
Cell extracts were prepared in 200 l lysis buffer containing 80% ice-cold
methanol/water (MtOH/H2O). The cells were subjected to ultrasonication with
a sonic Dismembator (Fisher Scientiﬁc, Fairland, NJ) on a power setting of 3
for 30 s. After centrifugation at 12,000 rpm for 10 min, the supernatant was
ﬁltered through a Microcon YM-3 ﬁlter (Millipore, Bedford, MA) at 4°C for 40
min and evaporated down to dryness using a Vacufuge Concentrator before
reconstitution in 50 l of water. The chromatographic system was set up as
described in a previous work (15) with minor modiﬁcations. The mass
spectrometer was operated in the negative ion mode with an electrospray
voltage of 4,000 V at 300°C and was supplied by auxiliary gas (30 psi) (15).
Quantiﬁcation was performed with Xcalibur software (Thermo Fisher Scien-
tiﬁc) using the standard addition method. Liver samples were extracted by
perchloric acid (HClO4) or potassium hydroxide (4) solution to determine
adenine and oxidized and reduced pyridine nucleotide contents, respectively.
Electrospray–ionization mass spectrometry was performed in positive ion
mode using a MDS Sciex API 4000 Triple Quadrupole Mass Spectrometer
(Applied Biosystems, Ontario, Canada) followed by chromatographic separa-
tion on an Agilent 1100 series high-performance liquid chromatography
system (Agilent Technologies, Palo Alto, CA) equipped with an XTerra MS C18
2.1  150 mm, 3.5-m column (Waters, Milford, MA), as previously described
(16).
Histochemistry and electron microscopy. Mouse tissues were ﬁxed with
formalin, dehydrated with ethanol, embedded in parafﬁn, and cut at a
thickness of 5 mol/l. Sections of epididymal fat, liver, soleus muscle, and
extensor digitorum longus (EDL) were prepared for hematoxylin and eosin
staining. Liver and muscle tissues were prepared as described previously (17)
for transmission electron microscopy (Tecnai G2 Spirit Twin; FEI Company;
Korea Basic Science Institute).
Enzyme assays. Cytoplasmic extracts were prepared from mouse tissues for
enzyme assays. NQO1 activity was measured as described previously (14).
This method measures the decrease in absorbance at 600 nm as a result of the
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FIG. 1. L-induced NADH oxidation stimulates the AMPK signaling pathway and mitochondrial fuel metabolism in NQO1-expressing cells. A:
Schematic illustration of NQO1-mediated chemical reaction. NADH is oxidized by providing two electrons to L, which is catalyzed by NQO1. B:
L6 myoblasts were treated with the indicated concentration of L for 30 min and extracted in lysis buffer containing 80% ice-cold methanol/water
(MtOH/H2O). Representative NAD
-to-NADH ratios were determined by liquid chromatography–mass spectroscopy/mass spectroscopy analysis as
described in RESEARCH DESIGN AND METHODS. All experiments were performed in triplicate. C: L-induced phosphorylations of AMPK and ACC.
Immunoblot analyses of the lysates from MEF treated with L( 5mol/l) for the indicated time periods were performed with antibodies to the
indicated proteins. D: Phosphorylation and activation of AMPK by Li nN Q O
/ and NQO1
/ MEFs. Phosphorylation of AMPK was estimated
by immunoblot analyses of the lysates from NQO
/ and NQO1
/ MEF treated with L( 5mol/l) or DMSO for 30 min, and the activity of AMPK
was measured by using the SAMS peptide assay. Error bars indicate SD. E: Phosphorylation of ACC was estimated by immunoblot analyses of the
lysates from NQO
/ and NQO1
/ MEF treated with L( 5mol/l) or DMSO for 30 min, and the activity of ACC was determined by quantifying
the ﬁxation of
14CO2 to acid-stable products. F–H: Comparison of CPT (F), 3-HAD (G) activities, or
14C-palmityl-CoA oxidation (H) between
DMSO- and L-treated L6 myoblasts. Error bars indicate SD (*P < 0.05; **P < 0.005).
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sured using a synthetic “SAMS” peptide substrate and [-
32P]ATP as described
previously (18). ACC activity was estimated by quantifying the ﬁxation of
14CO2 to acid-stable products (19). Carnitine palmitoyltransferase (CPT)
activity was measured by the transfer of
14C-carnitine into the mitochondria
matrix in L6 myoblasts and soleus muscle as described previously (19).
Hydroxyacyl-CoA dehydrogenase (HAD) activity was measured in L6 myo-
blasts by monitoring the conversion of acetoacetyl-CoA to L-3-hydroxybutyryl
CoA and the concomitant oxidation of NADH to NAD
. The reaction was
monitored at 340 nm as described previously (20).
Analysis of fatty acid oxidation and malonyl-CoA concentration.
14C-
palmityl-CoA (Perkin Elmer) oxidation by L was measured in L6 myoblasts
and soleus muscle using
14CO2 and 0.2 ml of benzethonium solution as
described previously (20). Malonyl-CoA was measured by high-performance
liquid chromatography as described previously (21).
Analysis of physiological indicators. O2 consumption was estimated as
described previously (22). For indirect calorimetry, individual mice were
placed in calorimetry chambers (Oxymax OPTO-M3 system; Columbus Instru-
ments, Columbus, OH) and allowed to adapt for 48 h. During the ﬁrst 24 h,
mice had free access to food and water, and during the second 24 h, the mice
had access to water only. Energy expenditure was calculated by measuring O2
consumption and CO2 production every 30 min for 24 h. For a cold-resistance
test, DIO mice were exposed to 4°C ambient temperature for 12 h and rectal
temperature was measured for 12 h. Blood samples were collected in
heparinized tubes and separated by centrifugation and stored at 20°C for
future use. Enzymatic colorimetry was used to quantify triglyceride, total
cholesterol, free fatty acid, and glucose (Beckman Instruments, Palo Alto,
CA). Plasma insulin (Linco Research, St. Charles, MO), TNF (R&D System),
adiponectin (Linco Research), resistin (KOMED), and leptin (Linco Research)
were quantiﬁed by ELISA as described previously (4,23–25).
DNA microarray and quantitative RT-PCR. Microarray analysis was
performed with pooled adipose, liver, or muscle tissue from adult male mice
treated with vehicle or L for 4 weeks. Total RNA was prepared from
homogenized tissues using Trizol reagent (Invitrogen, Carlsbad, CA). Probes
for microarray analysis were prepared from 10 g of total RNA and hybridized
to mouse 430A GeneChips (Affymetrix, Santa Clara, CA). The hybridized
arrays were scanned and raw data extracted using Microarray Analysis Suite
5.0 (Affymetrix). For quantitative PCR, cDNA was reverse transcribed from 1
g of total RNA with Superscript II and oligo primer (26). The resulting cDNAs
were ampliﬁed using a LightCycler FastStart DNA Master SYBR Green I kit
and LightCycler according to the manufacturer’s instructions (Roche Diagnos-
tics, Indianapolis, IN). Expression data were normalized to -actin.
Immunoblotting. Total proteins from liver, muscle (EDL and soleus), and
indicated cells were extracted in RIPA lysis buffer (500 mmol/l Tris-HCl pH
7.4, 1 mmol/l EDTA, 150 mmol/l NaCl, 1% NP-40, 0.25% Na-deoxycholate, and
1 mmol/l phenylmethylsulfonl ﬂuoride), and content was determined using the
Bio-Rad dye binding microassay (Bio-Rad Laboratories, Inc, Hercules, CA).
Protein (20 g per lane) was electrophoresed on a sodium dodecyl sulfate
SDS-polyacrylamide gel after boiling for 5 min in SDS sample buffer. Proteins
were blotted onto Hybond enhanced luminescence membranes (Amersham
Pharmacia Biotech, Arlington Heights, IL). After electroblotting, the mem-
branes were blocked with TBS and Tween 20 (10 mmol/l Tris-HCl pH 7.4, 150
mmol/l NaCl, and 0.1% Tween 20) containing 5% nonfat dry milk and incubated
with the primary antibody diluted in blocking buffer overnight at 4°C.
Membranes were then washed, incubated with the appropriate second anti-
bodies for1ha troom temperature, and rewashed. Blotted proteins were
detected by using enhanced chemiluminescence.
Results are expressed as means  SD. Differences between groups were
examined for statistical signiﬁcance using Student’s t test and ANOVA. The
difference was considered to be signiﬁcant if P 	 0.05.
RESULTS
Enhanced cytosolic NADH oxidation by NQO1 stim-
ulates cellular energy metabolism. We screened nat-
ural compounds that induce NADH oxidation in the
presence of NQO1. Interestingly, L and its structurally
related compounds, tanshinone 2A and cryptotanshinone,
rapidly induced NADH oxidation in vitro (supplemental
Fig. 1A, available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-1183/DC1). In
particular, L strongly decreased the ﬂuorescence inten-
sity of NADH in NQO1-expressing HepG2 cells but not in
NQO1-deﬁcient HEK293 cells, suggesting that NQO1 is
required for L-induced NADH oxidation (supplemental
Fig. 1B; available in the online appendix). Consistently,
HEK293 cells transfected with wild-type NQO1 but not
catalytically inactive NQO1 became responsive to L
(supplemental Fig. 1B, available in the online appendix).
We measured total NAD
 and NADH by the liquid
chromatography–mass spectroscopy/mass spectros-
copy method (15) in L6 muscle cells treated with
different doses of L. As expected, the NAD
-to-NADH
ratio was increased in L6 cells after L treatment (Fig.
1B). These results indicate that L induces NADH
oxidation only in the presence of NQO1 activity.
Because the intracellular NAD
-to-NADH ratio indicates
the energy status of cells (27,28), L-induced NADH oxi-
dation may stimulate the AMPK signaling pathway, a
well-known energy sensing pathway activated under en-
ergy depletion (6,7,29). In fact, L treatment dramatically
induced the activating phosphorylation in the catalytic
subunit of AMPK (AMPK T172) within 30 min (Fig. 1C
and supplemental Fig. 2A, available in the online appen-
dix). Moreover, AMPK-dependent inhibitory phosphoryla-
tion of ACC (S79) was also strongly induced in L-treated
cells (Fig. 1C and supplemental Fig. 2A, available in the
online appendix). To examine whether L-induced AMPK
activation requires NQO1 activity in vivo, we generated
NQO1 knockout mice and injected L into mouse embry-
onic ﬁbroblasts (MEFs) isolated from the heterozygous
(/) and homozygous (/) knockout mice. L-induced
phosphorylations of AMPK and ACC were not observed in
NQO1-deﬁcient MEFs but were observed in NQO
/ MEFs
(Fig. 1D–E). Consistent with these immunoblot results, L
treatment modulated AMPK and ACC activities only in
NQO
/ MEFs but not in NQO
/ MEFs (Fig. 1D–E).
Furthermore, NQO1-speciﬁc inhibitors, dicoumarol and
ES936, completely blocked L-induced AMPK phosphory-
lation (supplemental Fig. 2B, available in the online appen-
dix). These results collectively indicate that L induces
AMPK activation speciﬁcally by NQO1.
Because AMPK activation and concomitant ACC inhibi-
tion stimulate fatty acid oxidation (30,31), we measured
the activities of two representative metabolic enzymes
regulating mitochondrial fatty acid oxidation. Intriguingly,
the activities of CPT and 3-HAD were signiﬁcantly in-
creased in L-treated L6 myoblast cells (Fig. 1F–G). Con-
sistently, mitochondrial fatty acid oxidation measured by
14C-palmitoyl-CoA oxidation was substantially elevated in
L-treated cells (Fig. 1H). These results suggest that
L-induced NADH oxidation activates mitochondrial fuel
metabolism by stimulating the AMPK signaling pathway.
Pharmacological NADH oxidation stimulates activa-
tion of AMP-activated protein kinase and fatty acid
oxidation in vivo. To investigate the in vivo effects of L,
we examined L-induced metabolic changes in DIO mice.
Consistent with the cell data, L treatment highly in-
creased the NAD
-to-NADH ratio in the liver of DIO mice
(Fig. 2A). Moreover, L treatment substantially increased
the phosphorylations of AMPK and ACC and the activity of
AMPK in the liver, EDL, and soleus muscle of DIO mice
(Fig. 2B–E). We also monitored several enzymatic activi-
ties involved in mitochondrial fatty acid oxidation in the
soleus muscle of L-treated DIO mice. L treatment
signiﬁcantly reduced the activity of ACC and the level of
its metabolic product malonyl-CoA (32,33) in the soleus
muscle (Fig. 2F–G). In contrast, the activities of CPT and
HAD were highly increased in L-treated mice compared
with those of vehicle-treated mice (Fig. 2H–I). The rate of
mitochondrial fatty acid oxidation was much higher in
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creased NADH oxidation by L treatment stimulates the
AMPK signaling pathway and mitochondrial fatty acid
oxidation in vivo.
L reverses obesity and related phenotypes in diet-
induced obesity mice and ob/ob mice. To examine
whether L-induced NADH oxidation has a therapeutic
potential in treating metabolic syndrome, we systemati-
cally treated DIO mice with L for 8 weeks (Fig. 3,
supplemental Fig. 3). Surprisingly, the body weight of
L-treated mice continuously decreased throughout the
treatment, whereas that of the control mice slightly in-
creased (Fig. 3A). Interestingly, the food intake of L-
treated mice decreased during the ﬁrst 2 weeks of
treatment and then returned to the normal state (Fig. 3B)
because L-treated mice exhibited progressive weight loss
even after returning to the normal state of food intake (Fig.
3A–B). To observe the role of decreased food intake in the
early phase of L administration, we compared the body
weight of the L-treated group with that of the pair-fed
group. In Fig. 3C, the treated group (n 
 8) and pair-fed
group (n 
 8) showed 24.9  7.36% and 3.4  7.86%
weight loss compared with the baseline weight. A compari-
son of the weights of the treated and pair-fed groups to those
of the vehicle group showed that the L-treated and pair-fed
groups had weight losses of 33.6  5.78% and 10.5  3.00%,
respectively; thus, 23% of total weight loss can be attributed
to the peripheral actions of L (Fig. 3C, supplemental Fig. 3).
These ﬁndings suggest that a major factor governing body
weight loss in L-treated mice is likely to be increased energy
expenditure rather than decreased food intake.
Consistent with the decreased body weight, MRI of the
coronal and transverse sections of L-treated DIO mice
showed dramatic decreases in subcutaneous and visceral
adipose tissues (Fig. 3D). Moreover, the weights of subcuta-
neous, mesenteric, perirenal, and gonadal fats in L-treated
DIO mice were considerably decreased (supplemental Fig.
4), indicating that their body weight loss is the result of the
reduced adipose tissues. After analyzing various indicators of
glucose and fat metabolism in the sera of L-treated DIO
mice, we found overall decreased amounts of triglyceride,
cholesterol, free fatty acid, glucose, insulin, adiponectin,
resistin, and leptin in L-treated DIO mice (Table 1). Notably,
the adipocyte marker perilipin staining revealed that the size
of lipid droplets in the epididymal fat cells was much smaller
in L-treated DIO mice (Fig. 3E). Moreover, oil red O staining
in the liver showed that L treatment considerably sup-
pressed the liver steatosis in DIO mice (Fig. 3F). All these
dramatic metabolic changes, including reduced body weight
and adipocyte size, and decreased hepatic steatosis were
similarly observed in L-treated ob/ob mice (Fig. 4A–D).
Consistently, L treatment resulted in enhanced glucose
disposal rates and improved insulin sensitivity in both DIO
mice and Otsuka Long Evans Tokushima fatty type 2 diabetic
model rats (supplemental Fig. 5).We conclude that L treat-
ment can alleviate the key symptoms of metabolic syndrome
in the rodent models with obesity and diabetes.
Pharmacological NADH oxidation modulates expres-
sion of genes involved in metabolism and mitochon-
drial functions. To further understand the underlying
mechanisms of L-induced metabolic improvements, we
performed genomewide microarray analyses in the liver,
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involved in metabolism and mitochondrial functions were
differentially expressed in DIO mice exposed to L, and
quantitative RT-PCR experiments also veriﬁed these re-
sults (Table 2). For example, L treatment strongly in-
duced PGC-1 and nuclear respiratory factor-1, the master
regulators of mitochondrial biogenesis (34,35), in the liver
and muscle of DIO mice. In addition, mitochondrial met-
abolic genes (COX4 and COX7) were also upregulated in
the muscle of L-treated DIO mice. Interestingly, Sirt1 and
Sirt3, which are known to be activated in response to
calorie restriction (5,36,37), were also highly induced in
the muscle of L-treated mice. Moreover, genes related to
lipolysis (LPL and ATGL) and glucose uptake (GLUT4)
were upregulated in the adipose tissue of L-treated DIO
mice. However, fatty acid synthase and PPAR, which play
key roles in adipogenesis and fatty acid synthesis (38),
were downregulated in L-treated DIO mice. These re-
sults strongly suggest that L-induced NADH oxidation
stimulates mitochondrial biogenesis and functions and
also enhances energy metabolism by controlling global
gene expression related to cellular metabolism.
Long-term pharmacological NADH oxidation stimulates
mitochondrial biogenesis and energy expenditure. Be-
cause several genes affected by L treatment take part in
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TABLE 1
Metabolic parameters in mice treated with vehicle or L
Vehicle L
Triglyceride (mg/dl) 80.8  10.57 66.33  7.66*
Cholesterol (mg/dl) 219.8  52.84 140  19.34**
Free fatty acid (uEq/l) 1085  174.1 487  69.26**
Adiponectin (ng/ml) 21.74  4.63 8.4  1.02**
Resistin (ng/ml) 1.458  0.23 1  0.27**
TNFa (pg/ml) 19.88  4.03 22.82  7.1
Leptin (ng/ml) 128.8  13.85 33.47  17.56**
Glucose (mg/dl) 232.8  15.78 133.3  33.66**
Insulin (ng/dl) 4.1  1.49 1.68  0.95**
Data are means  SD. After oral administration with vehicle (n 
 5)
or L( n 
 6) for 4 weeks, metabolic parameters were analyzed. *P 	
0.05, **P 	 0.005 for the L-treated group versus the vehicle control
group.
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DIABETES, VOL. 58, APRIL 2009 969mitochondrial remodeling and biogenesis (34,39,40), we
examined the physiological and ultrastructural changes of
mitochondria in L-treated DIO mice. As a result, mito-
chondria in the liver of untreated DIO mice appeared to be
swollen, distorted, and deﬁcient in cristae and matrix (Fig.
5A–B). However, DIO mice treated with L for 8 weeks
showed an increased number of mitochondria with normal
morphologies such as well-organized cristae and matrix
structures (Fig. 5A–B). Furthermore, the mitochondria
collected from the soleus muscle in L-treated DIO mice
exhibited higher levels of mitochondrial DNA and complex
II subunit expression compared with those in untreated
controls, suggesting that L treatment actively induced
mitochondrial biogenesis (Fig. 5C). Consistently, the num-
ber of ﬁbers in the soleus muscle that showed strong
ATPase staining intensity and intermyoﬁbrillar mitochon-
dria was increased in L-treated DIO mice (Fig. 5D).
To further characterize the physiological effects of
mitochondrial restoration in L-treated DIO mice, we
measured two metabolic indices: respiratory oxygen
consumption and cold resistance. The quantity of resting
oxygen uptake (VO2) was markedly increased after adjust-
ing for body weight in L-treated DIO mice (Fig. 5E),
whereas the ratio of night respiratory exchange was
decreased (0.77, L-treated mice; 0.82, control mice; P 	
0.005, data not shown). However, VO2 that had not been
adjusted for body weight showed no statistical signiﬁ-
cance between control and L-treated groups. Thus, adi-
pose tissue mass, which is profoundly decreased by L
treatment, may be an important denominator for the
analysis of resting VO2. In addition, L-treated DIO mice
displayed much stronger cold resistance than the control
mice (Fig. 5F). More importantly, L treatment signiﬁ-
cantly increased energy expenditure of DIO mice (Fig.
5G). Overall, these results propose that increases in mito-
chondrial integrity, oxygen consumption, and energy ex-
penditure are the underlying mechanisms of Li n
assuaging the metabolic symptoms of DIO mice.
DISCUSSION
NAD
 and its derivatives are classic metabolites involved
in energy metabolism (11). Recent evidence suggests that
NAD
 is a central regulator in cellular energy metabolism.
Moreover, the importance of cellular NAD
 levels has
been highlighted by the discovery of SIR2-related proteins
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yeast and mammals (41). Yeast Sir2 and a mammalian
ortholog sirtuin, Sirt1, are NAD
-dependent deacetylases
that are regulated by the NAD
-to-NADH ratio (5). Accu-
mulating evidence has suggested that NAD
-to-NADH ratios
are altered in various pathological conditions such as neuro-
degeneration, diabetes, and oxidative stress (28,42). The
pharmacological activation of NAD
-dependent SirT1 com-
pensates for the effects of a high-calorie diet (10). Based on
these observations, pharmacological induction of higher
NAD
-to-NADH would be expected to ameliorate the meta-
bolic syndrome.
NQO1 is a ﬂavoenzyme that uses NAD(P)H as an elec-
tron donor to catalyze the reduction of substrates. Previ-
ous studies and our data suggest that L is a speciﬁc and
high-afﬁnity substrate of NQO1 in vitro and in vivo (14). L
would therefore have the propensity to induce a higher
NAD
-to-NADH ratio. The expression of NQO1, a target of
L, is highly upregulated in liver, muscle, and fat tissues,
which are important for the regulation of whole-body
energy metabolism and insulin sensitivity (supplemental
Fig. 6). The promoter of the NQO1 gene has an antioxidant
response element that serves as the binding motif for the
factor Nrf2, which is activated by reactive oxygen species
(ROS) stimuli. The increased ROS stimulation in metabol-
ically active tissues under obesity and diabetic conditions
may activate Nrf2 and NQO1 gene expression. Consis-
tently, Palming et al. (43) found that human adipocytes
have high NQO1 expression and that NQO1 expression
levels were positively correlated with adiposity, glucose
tolerance, and markers of liver dysfunction. Taken to-
gether, NQO1 would appear to be a useful pharmacologi-
cal target for the induction of higher NAD
-to-NADH
ratios in obesity and diabetes models.
We have shown that the enhanced NADH oxidation
induced by L in NQO1-present cells increases phosphor-
ylation and activation of AMPK. The reduced cytosolic
NADH levels induced by L treatment may disturb the
proper distribution of NADH reducing equivalents in mi-
tochondrial complexes for energy production, suggesting
that L may transiently increase AMP levels and activate
AMPK to compensate for cellular energy depletion
(10,36,44). Two upstream kinases, LKB1 and CaMKK, are
involved in the phosphorylation of the catalytic subunit of
AMPK (45,46). We tested the effects of Lo nA M P K
phosphorylation in LKB1-deﬁcient MEFs. AMPK phos-
phorylation was only observed at very early time points
(30 s to 5 min) after treatment with L in LKB1-deﬁcient
cells (data not shown). This pattern of AMPK activation is
quite different from that observed in cells with normal
LKB1 expression (supplemental Fig. 2A), in which L
resulted in prolonged AMPK phosphorylation. The CaMKK
inhibitor (STO609) completely abolished the early phase
of AMPK phosphorylation (data not shown). These ﬁnd-
ings strongly suggest that both LKB1 and CaMKK are
required for full activation of AMPK under L-induced
AMPK phosphorylation conditions. Activation of AMPK
led to increased fatty acid oxidation by inactivating ACC
phosphorylation. Consistently, L-mediated AMPK activa-
tion induces ACC phosphorylation and activation of CPT
and HAD, resulting in beneﬁcial fatty acid oxidation.
Taken together, these ﬁndings suggest that pharmacolog-
ical stimulation of NADH oxidation leads to increased
mitochondrial fatty acid oxidation.
We additionally examined whether L-induced NADH
oxidation could be used as a therapy for treating obesity,
a major component of metabolic syndrome. Pair-feeding
studies (Fig. 3C, supplemental Fig. 3) clearly demon-
strated that loss of weight induced by L is mediated by
both central and peripheral actions. Although a decrease
of food intake after L treatment was noted in the early
phase of treatment, food intake recovered with continued
L administration. We found that intracranial administra-
tion of L in mice resulted in a dramatic decrease in
feeding behavior (data not shown); however, it is unclear
which mechanism in the hypothalamus mediates the L-
induced decrease in food intake. Long-term weight loss
induced by L is mainly the result of the peripheral action
of L and its weight-reducing effect, which are accompa-
nied by a smaller fat mass; lower fatty inﬁltration in the
liver; decreased levels of plasma insulin, triglyceride, and
glucose; and increased glucose disposal rates after insulin
TABLE 2
Expression of genes related to energy metabolism and mitochon-
drial functions in the liver, muscle, and white adipose tissue
Tissue Genes
Relative mRNA levels
(L/vehicle group)
PGC1 3.46  2.1*
Liver NRF-1 1.88  0.38*
mtTFA 1.32  0.32
CPT1 1.56  0.29*
UCP2 3.06  0.67**
AMPK1 1.84  0.64*
AMPK2 1.42  0.39
PPAR 1.00  0.25
Muscle PGC1 1.70  0.31*
NRF-1 1.60  0.42*
mtTFA 0.81  0.45
CPT1 1.07  0.48
COX4 2.18  0.45*
COX7 1.69  0.36
GLUT2 5.08  4.55
GLUT4 1.45  0.89
PPAR 1.45  0.42
AMPK1 2.80  1.71
AMPK2 1.69  1.33
SIRT1 2.05  0.44*
SIRT3 3.33  0.84*
UCP2 2.27  1.22
UCP3 2.78  1.75
Gonadal fat (WAT) PGC1 2.02  0.3**
NRF-1 1.71  1.08
FASN 0.32  0.13*
LPL 2.12  0.37**
ATGL 2.34  0.38**
SCD1 0.68  0.26
AOX 1.58  0.4*
GLUT2 2.10  1.2
GLUT4 5.20  0.82**
PPAR 2.36  0.32**
PPAR 0.51  0.23*
SIRT1 1.45  0.18**
SIRT2 1.33  0.15**
SIRT3 4.33  0.91*
Data are means  SD. After oral administration with vehicle (n 
 5)
or L( n 
 6) for 4 weeks, relative mRNA levels in the indicated
tissues were analyzed by quantitative RT-PCR. The values indicate
relative mRNA levels of L-treated groups compared to those of
vehicle control groups. *P 	 0.05, **P 	 0.005 for the L-treated
group versus the vehicle control group.
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oxidation induced by L could lead to an amelioration of
key components of metabolic syndrome in rodent models
with obesity and diabetes.
The reversal of obesity and other phenotypes of DIO and
ob/ob mice by L is associated with the normalization of
disorganized mitochondrial ultrastructure and increased
numbers of mitochondria. Mitochondrial dysfunctions are
frequently associated with obesity and diabetes, and im-
provements in obesity and glucose tolerance are associ-
ated with enhanced mitochondrial oxphos functions and
biogenesis (47,48). En examination of the gene expression
patterns after L treatment showed increased expression
of PGC-1 and SirT family genes in liver, muscle, and
adipose tissues. Prolonged AMPK activation is known to
increase PGC-1 expression, SirT1 activity, and mitochon-
drial biogenesis. Taken together, it is plausible that AMPK
activation by L induces PGC-1, a master regulator of
mitochondrial biogenesis, and Sirt1, a mediator of calorie-
restriction effects, which promote higher mitochondrial
biogenesis and energy expenditure in mice. The resting
VO2 was found to be higher in the L-treated group than in
the vehicle group after adjusting for body weight. How-
ever, this ﬁnding does not necessarily indicate that L
treatment increases resting metabolic rate because
changes of body weight, including fat mass, may affect
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bolic rate, additional analysis of submaximal and maximal
VO2 with or without adjustments for body composition will
be required. The consequences of long-term physiological
adaptations on enhanced NADH oxidation after L treat-
ment will require further study to prove the potential of L
as a new treatment for obesity and diabetes.
Previous studies showed that L inhibits tumorigenesis
and that NQO1 mediates this effect of L (13,14). Interest-
ingly, the cytotoxic effect of L was prominently observed
in cultured cancer cells, whereas it was barely detectable
in normal primary cultured cells (supplemental Fig. 7)
(49). Although primary cultured MEFs showed strong
resistance to L cytotoxicity, 10% of the MEFs under-
went cell death (supplemental Figs. 7 and 8). This phe-
nomenon was completely suppressed by adding palmitate
to the culture medium (supplemental Fig. 8), suggesting
that increased palmitate oxidation compensates L cyto-
toxicity. These data suggest that L-induced cell death
occurs selectively in cancer cells that exhibit reduced
mitochondrial oxidative phosphorylation. Although the
systemic toxicity of L in humans has not been fully
established, ARQ501, a synthetic version of L, has been
subjected to phase I and II clinical trials and only mild
adverse effects such as anemia and fatigue have been
observed. It is indispensable to evaluate the systemic
toxicity of L using different administration routes, formu-
las, and exposure times.
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